Edward. J. Oberle

Edward. J. Oberle

Auto-generated profile, based on publicly available information

Edward. J. Oberle

Nationwide Children's Hospital and The Ohio State University Columbus

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2017 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
SKSusan Kim
Susan Kim
PKPhilip Kahn
Philip Kahn
ARAngela B. Robinson
Angela B. Robinson
BLBianca Lang
Bianca Lang
ASAndrew Shulman
Andrew Shulman
AHAdam M. Huber
Adam M. Huber
Juvenile dermatomyositis (JDM) is the most common form of the idiopathic inflammatory myopathies in children. A subset of children have the rash of JDM without significant weakness, and the optimal treatments for these children are unknown. The goal of this study was to describe the development of consensus clinical treatment plans (CTPs) for children with JDM who have active skin rashes, without significant muscle involvement, referred to as skin predominant JDM in this manuscript. The Children’s Arthritis and Rheumatology Research Alliance (CARRA) is a North American consortium of pediatric rheumatology health care providers. CARRA members collaborated to determine consensus on typical treatments for JDM patients with skin findings without significant weakness, to develop CTPs for this subgroup of patients. We used a combination of Delphi surveys and nominal group consensus meetings to develop these CTPs. Consensus was reached on patient characteristics and outcome assessment, and CTPs were developed and finalized for patients with skin predominant JDM. Treatment option A included hydroxychloroquine alone, Treatment option B included hydroxychloroquine and methotrexate, and Treatment option C included hydroxychloroquine, methotrexate and corticosteroids. Three CTPs were developed for use in children with skin predominant JDM, which reflect typical treatment approaches. These are not considered to be specific recommendations or standard of care. Using the CARRA network and prospective data collection, we will be able to apply statistical methods in the future to allow comparisons of JDM patients following these consensus treatment plans.

30 July 2021 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
PVPatricia Vega‐Fernandez
Patricia Vega‐Fernandez
TTTracy V. Ting
Tracy V. Ting
EOEdward J. Oberle
Edward J. Oberle
CMCourtney McCracken
Courtney McCracken
JFJanet Figueroa
Janet Figueroa
FWFor The Carra Musculoskeletal Ultrasound Workgroup
For The Carra Musculoskeletal Ultrasound Workgroup

11 April 2020 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
PWPamela F. Weiss
Pamela F. Weiss
TBTimothy G. Brandon
Timothy G. Brandon
JBJohn Bohnsack
John Bohnsack
MBMerav Heshin Bekenstein
Merav Heshin Bekenstein
MFMichael L. Francavilla
Michael L. Francavilla
NCNancy A. Chauvin
Nancy A. Chauvin

13 July 2023 in Arthritis Care & Research
Verified
Journal Article
Open access
CBCatherine April Bingham
Catherine April Bingham
JHJulia G. Harris
Julia G. Harris
TQTingting Qiu
Tingting Qiu
MGMileka Gilbert
Mileka Gilbert
SVSheetal S Vora
Sheetal S Vora
FNfor the Pediatric Rheumatology Care and Outcomes Improvement Network
for the Pediatric Rheumatology Care and Outcomes Improvement Network
Objective: To describe the selection, development, and implementation of quality measures (QMs) for juvenile idiopathic arthritis (JIA) by the Pediatric Rheumatology Care and Outcomes Improvement Network (PR‐COIN), a multihospital learning health network using quality improvement methods and leveraging QMs to drive improved outcomes across a JIA population since 2011.Methods: An American College of Rheumatology–endorsed multistakeholder process previously selected initial process QMs. Clinicians in PR‐COIN and parents of children with JIA collaboratively selected outcome QMs. A committee of rheumatologists and data analysts developed operational definitions. QMs were programmed and validated using patient data. Measures are populated by registry data, and performance is displayed on automated statistical process control charts. PR‐COIN centers use rapid‐cycle quality improvement approaches to improve performance metrics. The QMs are revised for usefulness, to reflect best practices, and to support network initiatives.Results: The initial QM set included 13 process measures concerning standardized measurement of disease activity, collection of patient‐reported outcome assessments, and clinical performance measures. Initial outcome measures were clinical inactive disease, low pain score, and optimal physical functioning. The revised QM set has 20 measures and includes additional measures of disease activity, data quality, and a balancing measure.Conclusion: PR‐COIN has developed and tested JIA QMs to assess clinical performance and patient outcomes. The implementation of robust QMs is important to improve quality of care. PR‐COIN's set of JIA QMs is the first comprehensive set of QMs used at the point‐of‐care for a large cohort of JIA patients in a variety of pediatric rheumatology practice settings.

21 February 2023 in Arthritis Care & Research
Verified
Journal Article
Open access
PVPatricia Vega‐Fernandez
Patricia Vega‐Fernandez
EOEdward J. Oberle
Edward J. Oberle
MHMichael Henrickson
Michael Henrickson
JHJennifer Huggins
Jennifer Huggins
SPSampath Prahalad
Sampath Prahalad
FIfor the Childhood Arthritis and Rheumatology Research Alliance Investigators
for the Childhood Arthritis and Rheumatology Research Alliance Investigators
Objective: To determine the frequency of subclinical synovitis on musculoskeletal ultrasonography (MSUS) in juvenile idiopathic arthritis (JIA) and correlate patient‐ and provider‐reported outcome measures with MSUS synovitis.Method: JIA patients with an active joint count (AJC) of >4 underwent a 42‐joint MSUS performed at baseline and 3 months. B‐mode and power Doppler images were obtained and scored (range 0–3) for each of the 42 joints. Outcomes evaluated included physician global assessment of disease activity (PhGA), patient global assessment of disease activity (PtGA), patient pain, Childhood Health Assessment Questionnaire (C‐HAQ), and AJC. Subclinical synovitis was defined as synovitis detected by MSUS only. Generalized estimation equations were used to test the relationship between clinical arthritis (positive/negative) and subclinical synovitis (positive/negative). Spearman's correlation coefficients (rs) were calculated to determine the association between MSUS synovitis and patient‐ and physician‐reported outcomes.Results: In 30 patients, subclinical synovitis was detected in 30% of joints. Clinical arthritis of the fingers, wrists, and knee joints was significantly associated with MSUS synovitis in these joints. PtGA and the C‐HAQ had a moderate (rs = 0.44, P = 0.014) to weak (rs = 0.37, P = 0.045) correlation with MSUS synovitis. There was a statistically significant strong correlation between MSUS synovitis and PhGA (rs = 0.61, P = 0.001), but a weak correlation with AJC (rs = 0.37, P = 0.048) at the follow‐up visit.Conclusion: Subclinical synovitis was commonly observed in this cohort of JIA patients. The fair‐to‐moderate correlation of MSUS synovitis with patient‐ and provider‐reported outcomes suggests that MSUS assesses a different, possibly more objective, domain not determined by traditional JIA outcome measurements.

1 February 2022 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
TTTala El Tal
Tala El Tal
MRMeghan E. Ryan
Meghan E. Ryan
BFBrian Michael Feldman
Brian Michael Feldman
CBCatherine April Bingham
Catherine April Bingham
JBJon M. Burnham
Jon M. Burnham
EMEsi M. Morgan
Esi M. Morgan
Objective: Treat to target (T2T) is a strategy of adjusting treatment until a target is reached. An international task force recommended T2T for juvenile idiopathic arthritis (JIA) treatment. Implementing T2T in a standard and reliable way in clinical practice requires agreement on critical elements of (1) target setting, (2) T2T strategy, (3) identifying barriers to implementation, and (4) patient eligibility. A consensus conference was held among Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) stakeholders to inform a statement of understanding regarding the PR-COIN approach to T2T.Methods: PR-COIN stakeholders including 16 healthcare providers and 4 parents were invited to form a voting panel. Using the nominal group technique, 2 rounds of voting were held to address the above 4 areas to select the top 10 responses by rank order.Results: Incorporation of patient goals ranked most important when setting a treatment target. Shared decision making (SDM), tracking measurable outcomes, and adjusting treatment to achieve goals were voted as the top elements of a T2T strategy. Workflow considerations, and provider buy-in were identified as key barriers to T2T implementation. Patients with JIA who had poor prognostic factors and were at risk for high disease burden were leading candidates for a T2T approach.Conclusion: This consensus conference identified the importance of incorporating patient goals as part of target setting and of the influence of patient stakeholder involvement in drafting treatment recommendations. The network approach to T2T will be modified to address the above findings, including solicitation of patient goals, optimizing SDM, and better workflow integration.